Tirzepatide in Con Dao: Understanding Durability of Weight Change and Weight Regain Research

1. Why Durability Matters in Tirzepatide Research

Tirzepatide is a dual GIP and GLP-1 receptor agonist used in approved clinical settings to improve glycemic control and, depending on the product and jurisdiction, manage chronic weight-related disease. It influences appetite, food intake, glucose regulation, and other metabolic processes. Clinical trials have demonstrated that tirzepatide can produce substantial reductions in body weight. However, the amount of weight lost during treatment is only one part of the evidence needed to understand its role in long-term obesity management. Researchers also need to ask:

• How much of the initial weight reduction is maintained over time?
• What happens when treatment is discontinued?
• Do changes in blood pressure, glucose, lipids, and waist circumference persist?
• Does weight regain occur gradually or rapidly?
• How do study design, patient characteristics, and the duration of follow-up affect the findings?

These questions matter because obesity is a chronic, relapsing condition. Body weight is regulated by multiple biological and environmental factors, and the processes that support weight reduction during treatment may change after the treatment is withdrawn. For readers in Con Dao researching tirzepatide, the central distinction is between **efficacy during treatment** and **durability after treatment**. They are related, but they are not interchangeable.

2. What Does “Weight Durability” Mean?

Durability describes whether a treatment’s effects persist over time. In weight-management research, it can refer to the maintenance of weight reduction during ongoing treatment or the persistence of benefits after treatment has ended. These are different research questions. On-treatment durability asks whether a person continues to maintain or extend weight reduction while receiving treatment over a longer period. Post-treatment durability asks whether the weight reduction and associated health improvements persist after the medicine is discontinued. A study can demonstrate excellent on-treatment durability without demonstrating that the effect will persist after withdrawal. Researchers also distinguish absolute weight change from the proportion of previously lost weight that is regained. For example, a person who loses 20 kg and later regains 5 kg has regained 25% of the initial loss, but remains 15 kg below their starting weight. This is different from saying that the person has regained 25% of their body weight. Clear definitions are essential when interpreting trial results and media headlines.

3. SURMOUNT-4: The Key Randomized Withdrawal Trial

The SURMOUNT-4 trial, published in JAMA in 2024, directly examined what happens when adults who have lost weight with tirzepatide either continue treatment or switch to placebo [1]. The study had two phases:

1. Open-label lead-in: Participants received tirzepatide for 36 weeks, with treatment adjusted to a maximum tolerated dose of 10 mg or 15 mg once weekly.
2. Randomized withdrawal: Participants who completed the lead-in period and met the randomization criteria were assigned to continue tirzepatide or switch to placebo for another 52 weeks. Lifestyle counseling continued in both groups.

During the initial 36 weeks, participants experienced a mean body-weight reduction of 20.9%. During the subsequent randomized phase, outcomes diverged sharply between the groups. The difference between the randomized groups was statistically significant. The trial therefore provides direct evidence that, in the study population, continuing tirzepatide was more effective than switching to placebo for maintaining and extending weight reduction [1]. The findings should still be interpreted within the study design. Participants had already completed 36 weeks of treatment before randomization, so the withdrawal phase did not represent everyone who might begin tirzepatide in routine clinical practice. The study also excluded people with diabetes and did not test every possible approach to long-term maintenance.

4. What Does Weight Regain After Discontinuation Actually Mean?

Weight regain is often described as a simple return to the starting point. In research, the situation is more nuanced. Participants who switched to placebo in SURMOUNT-4 regained an average of 14.0% of their body weight during the randomized withdrawal phase. That figure represents a change from their weight at the time of randomization, after the initial treatment-associated weight reduction. It does not mean that they regained 14% of the weight they had lost, nor that everyone returned to their original baseline weight. At week 88, the placebo-switch group remained an average of 9.9% below its original baseline weight. This illustrates that substantial regain can coexist with a remaining net weight reduction. The proportion of weight regained also varies between individuals. Some regain a relatively small share of their initial loss; others regain most of it. Average trial results summarize the group and should not be treated as a precise forecast for any one person.

5. What Happens to Metabolic Improvements When Weight Returns?

Weight change is only one outcome of tirzepatide treatment. Researchers also measure waist circumference, blood pressure, lipid levels, blood glucose, glycated hemoglobin (HbA1c), and other cardiometabolic markers. A post hoc analysis of SURMOUNT-4, published in JAMA Internal Medicine in 2026, examined the relationship between the amount of weight regained after tirzepatide withdrawal and changes in cardiometabolic parameters [2]. Among participants who had initially achieved clinically meaningful weight reduction, greater regain was associated with a greater reversal of several improvements observed during active treatment. Examples included:

• Waist circumference: Participants with greater weight regain experienced larger increases in waist circumference.
• Systolic blood pressure: Larger regain categories showed greater increases in systolic blood pressure during the withdrawal phase.
• Glycemic measures: HbA1c increased more in groups with greater weight regain.
• Lipid and insulin measures: Several improvements in lipid-related and insulin-related markers also moved back toward less favorable levels as weight regain increased.

The analysis supports the view that weight regain may be accompanied by a partial reversal of metabolic improvements. It does not establish that weight regain was the sole cause of every change, because the analysis was post hoc and participants were not randomized to different amounts of regain. The practical research lesson is that durability should be assessed across several endpoints, not body weight alone.

6. Longer-Term Treatment: What SURMOUNT-1 Adds

The SURMOUNT-1 trial provides complementary evidence about sustained weight reduction during longer treatment. A prespecified subgroup of participants with obesity and prediabetes received tirzepatide or placebo for 176 weeks, followed by a 17-week off-treatment period [3]. At week 176, the mean percentage change in body weight was: The trial also found a markedly lower incidence of progression to type 2 diabetes in the tirzepatide groups during the treatment period. The reported incidence was 1.3% with tirzepatide compared with 13.3% with placebo among participants with obesity and prediabetes [3]. These findings demonstrate that substantial weight reduction can be sustained over three years while treatment continues in the studied population. The 17-week off-treatment period adds some information about outcomes after discontinuation, but it is relatively short compared with the full treatment period. The study does not establish that weight reduction will remain unchanged for years after treatment stops. This distinction is important: **long-term success during treatment is evidence of treatment durability, not proof of indefinite persistence after withdrawal.**

7. Evidence After Discontinuation: Findings From SURMOUNT-CN

A follow-up study of participants who completed the SURMOUNT-CN trial examined weight change during the 26 weeks after the 52-week treatment period ended [4]. In this observational follow-up, participants previously assigned to tirzepatide had regained weight by week 78 compared with their weight at the end of treatment. Mean weight changes during the post-treatment follow-up were:

• 9.1% in the group previously receiving tirzepatide 10 mg;
• 12.3% in the group previously receiving tirzepatide 15 mg; and
• 1.8% in the group previously receiving placebo.

Despite the regain, participants in the former tirzepatide groups remained below their original trial baseline at week 78, with mean net weight changes of −8.7% and −10.6% in the former 10 mg and 15 mg groups, respectively [4]. The study also reported residual improvements in several cardiometabolic indicators. These findings show that the consequences of discontinuation are not necessarily an immediate, complete loss of every benefit. However, this was a follow-up study rather than a new randomized comparison of different post-treatment strategies. It cannot determine which approach would best maintain weight reduction after treatment ends.

8. What the 2026 Systematic Review Says About Weight Regain

A systematic review and meta-analysis published in The BMJ in January 2026 examined weight regain after stopping medications used for weight management [5]. The review included 37 studies, covering 9,341 participants across 63 intervention arms. It included several types of weight-management medications, including incretin-based treatments such as tirzepatide and semaglutide. Across the broader group of weight-management medications, the estimated average rate of weight regain was 0.4 kg per month. For the subgroup of newer, more effective incretin mimetics—semaglutide and tirzepatide—the estimated rate was 0.8 kg per month, with a 95% confidence interval of 0.7 to 0.9 kg per month. The authors estimated that the average weight regain after stopping these newer incretin mimetics could reach 9.9 kg within the first year. They projected a return to baseline weight at around 1.5 years for this subgroup, but that projection should be interpreted cautiously because follow-up data for the newer medicines did not extend beyond 52 weeks in the included evidence [5]. These figures are pooled estimates, not tirzepatide-only predictions for an individual. The analysis combined studies with different populations, treatments, follow-up periods, and designs. It also found that cardiometabolic markers tended to move back toward baseline after medication cessation. The review supports a broad conclusion: weight regain after stopping weight-management medication is common and can occur relatively quickly. It does not mean every person will regain all the weight lost, or that the same rate applies to everyone.

9. Why Can Weight Regain Occur?

Weight regulation is influenced by appetite, satiety, energy expenditure, behavior, sleep, environment, and biological adaptations to weight loss. Tirzepatide acts on GIP and GLP-1 receptors and affects several processes involved in appetite and metabolic regulation. While treatment continues, these effects can help support reduced food intake and weight reduction. When the medicine is discontinued, its pharmacological effects diminish. Appetite regulation and energy balance may shift, making it harder to maintain the reduced weight. Weight loss itself can also trigger physiological adaptations that favor weight regain. This does not mean that weight regain is inevitable for every individual, nor does it imply a lack of effort. It reflects the interaction between a chronic condition, biological regulation, and the support available after treatment. Lifestyle measures remain important components of obesity management. However, the withdrawal trials show that lifestyle counseling alone did not prevent substantial average regain in the placebo-switch group of SURMOUNT-4. That observation should not be interpreted as evidence that nutrition, physical activity, sleep, or behavioral support are useless. Rather, it shows that these measures may not fully replace the pharmacological effects of tirzepatide for everyone.

10. What Durability Research Does Not Yet Tell Us

Although the evidence on tirzepatide withdrawal is growing, important uncertainties remain. First, study populations differ. SURMOUNT-4 enrolled adults with overweight or obesity without diabetes who completed the lead-in phase. SURMOUNT-1’s 176-week analysis focused on participants with obesity and prediabetes. Findings should not automatically be generalized to every person who receives tirzepatide. Second, follow-up after stopping is limited. Randomized withdrawal evidence is particularly informative over the first year, but it does not fully define outcomes over five or ten years. Third, not every possible maintenance strategy has been compared. Studies that switch participants to placebo answer a specific question. They do not establish the comparative effectiveness of all possible combinations of behavioral support, alternative therapies, and ongoing medical care. Fourth, averages conceal individual variation. Some participants regain more weight than others, and the extent of regain can be associated with differences in metabolic outcomes. Finally, weight is not the only meaningful endpoint. Long-term research should also examine cardiometabolic health, physical function, quality of life, adverse events, and other outcomes relevant to the patient population.

11. How to Interpret Durability Claims

The following framework helps distinguish what different kinds of evidence can support.

12. Frequently Asked Questions

1. Does weight loss from tirzepatide last after stopping treatment?

Not necessarily. Randomized withdrawal studies show that many participants regain a substantial amount of weight after stopping tirzepatide. Some remain below their original baseline, but long-term outcomes vary.

2. How much weight did participants regain in SURMOUNT-4?

Participants who switched to placebo regained an average of 14.0% of their body weight during the 52-week randomized withdrawal phase. This is a change from their weight at randomization, not the percentage of the initial weight loss regained.

3. Did everyone who stopped tirzepatide return to their starting weight?

No. At week 88, the placebo-switch group remained an average of 9.9% below its original baseline weight. Group averages do not describe every individual’s response.

4. Does continuing tirzepatide help maintain weight reduction?

In SURMOUNT-4, participants who continued tirzepatide lost an additional 5.5% of body weight during the 52-week randomized phase, while those switched to placebo regained weight on average. This demonstrates a group-level benefit of continued treatment in the study population.

5. Do metabolic improvements reverse when weight is regained?

A 2026 post hoc analysis of SURMOUNT-4 found that greater weight regain was associated with a greater reversal of several improvements in waist circumference, blood pressure, lipids, and glycemic measures. The findings indicate an association and do not prove that weight regain alone caused every change.

6. Does long-term treatment guarantee permanent weight loss?

No. SURMOUNT-1 showed sustained weight reduction over 176 weeks while treatment continued in participants with obesity and prediabetes. It did not establish that the same reduction persists indefinitely after discontinuation.

7. Is weight regain proof that tirzepatide failed?

No. Regain after discontinuation does not erase the weight reduction or clinical benefits achieved during treatment. It does, however, demonstrate why maintenance and longer-term care are important parts of obesity management.

8. Can lifestyle changes prevent all weight regain after tirzepatide withdrawal?

The evidence does not show that lifestyle changes reliably prevent all regain. Lifestyle support remains important, but substantial average regain occurred in the placebo-switch group of SURMOUNT-4 despite continued lifestyle counseling.

9. What does the 2026 BMJ review say about stopping weight-management medication?

The review found that weight regain commonly followed medication cessation and that cardiometabolic markers tended to move back toward baseline. Its estimates combine several medications and study designs, so they should not be treated as a precise prediction for a particular tirzepatide user.

10. What should readers in Con Dao look for when comparing tirzepatide durability claims?

Check the study’s population, treatment duration, follow-up after discontinuation, definition of weight regain, comparator, and cardiometabolic outcomes. Distinguish randomized trials from observational follow-up, and do not assume that an average result predicts an individual’s response.

13. Related Educational Resources

• Vietnam Peptides Knowledge Hub — explore educational articles about peptide science, clinical evidence, and weight-management research.
• Peptide Research FAQ — review general questions about research compounds, product information, and evidence limitations.
• Peptide Products and Research Information — distinguish commercial product descriptions from clinical evidence and regulatory authorization.
• Fat Loss Peptide Plan — a related educational resource; it should not be interpreted as a substitute for individualized medical care or evidence-based obesity treatment.

14. Related Research Product

15. Scientific References

1. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. https://doi.org/10.1001/jama.2023.24945
2. Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Internal Medicine. 2026;186(2):157–167. https://doi.org/10.1001/jamainternmed.2025.6112
3. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. 2025;392:958–971. https://doi.org/10.1056/NEJMoa2410819
4. Chen C, Ying Z, Tang Q, et al. Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial. Life Metabolism. 2025;4(5):loaf024. https://doi.org/10.1093/lifemeta/loaf024
5. West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. https://doi.org/10.1136/bmj-2025-085304
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216. https://doi.org/10.1056/NEJMoa2206038
7. US Food and Drug Administration. ZEPBOUND (tirzepatide) prescribing information. See the current official label for approved indications, contraindications, warnings, and safety information. FDA Drugs@FDA database
8. ClinicalTrials.gov. SURMOUNT-4: Study of Tirzepatide in Participants With Obesity or Overweight. Identifier NCT04660643. Trial record

Conclusion

Tirzepatide research shows that substantial weight reduction can be achieved and maintained during treatment, but durability after discontinuation is a separate clinical question. In SURMOUNT-4, participants who continued tirzepatide maintained and extended their initial weight reduction, while those switched to placebo regained substantial weight over the following year. A 2026 post hoc analysis also found that greater regain was associated with a greater reversal of several cardiometabolic improvements. Longer-term evidence from SURMOUNT-1 demonstrates sustained weight reduction over 176 weeks in participants with obesity and prediabetes while treatment continued. Follow-up after treatment cessation suggests that some benefits may persist temporarily even as weight returns, but the long-term course remains incompletely defined. For readers in Con Dao and elsewhere, the key lesson is to evaluate weight loss, maintenance, and post-treatment regain as distinct outcomes. Regain does not mean that prior treatment had no benefit, and average study results cannot predict every individual’s trajectory. It does mean that obesity management should account for the possibility of regain, the chronic nature of the condition, and the importance of ongoing clinical care. The strongest evidence supports planning for durability rather than assuming that weight loss will automatically persist after a medication is stopped.